📊 Eli Lilly (NYSE: LLY) | Strong Business, Attractive Valuation?
Eli Lilly's promising Retatrutide results reinforce its competitive position in the rapidly expanding obesity and diabetes treatment markets. However, strong fundamentals don't automatically justify a premium stock valuation.
🔹 Fundamentals: Robust revenue growth, high profit margins, and a promising drug pipeline support long-term growth potential.
🔹 Valuation: Analysts' average price target is approximately $1,334, while Morningstar estimates fair value at $980, highlighting significant differences in growth and risk assumptions.
🔹 Key Risks: Increasing competition, drug pricing pressures, regulatory uncertainty, and potential P/E multiple compression.
🎯 My Investment Approach:
1. Avoid chasing positive headlines or short-term momentum.
2. Review Q3 earnings and updated management guidance before making investment decisions.
3. Consider gradual accumulation at more attractive valuations, with $1,000–$1,100 as a preliminary area of interest, provided fundamentals remain intact.
4. Maintain a 5–10 year investment horizon, monitoring earnings growth, free cash flow, and market share.
⚠️ Important: With Q3 earnings scheduled for October 29, valuation assumptions and potential entry levels should be reassessed following the announcement.
💡 Bottom Line: A great company isn't necessarily a great investment at any price. Long-term returns depend not only on business growth but also on the valuation investors pay today.
Disciplined investing begins with valuation, not excitement.
For educational discussion only. Not financial advice (DYOR)